+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ataxia Drug"

From
Spinocerebellar Ataxias - Pipeline Insight, 2022 - Product Thumbnail Image

Spinocerebellar Ataxias - Pipeline Insight, 2022

  • Clinical Trials
  • August 2022
  • 100 Pages
  • Global
From
Ataxia - Pipeline Insight, 2022 - Product Thumbnail Image

Ataxia - Pipeline Insight, 2022

  • Clinical Trials
  • May 2022
  • 120 Pages
  • Global
From
Ataxia - Market Insight, Epidemiology and Market Forecast -2032 - Product Thumbnail Image

Ataxia - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • January 2022
  • 200 Pages
  • Global
From
From
From
Ataxia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Ataxia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Spinocerebellar Ataxias - Epidemiology Forecast to 2032 - Product Thumbnail Image

Spinocerebellar Ataxias - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Friedreich's Ataxia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Friedreich's Ataxia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Friedreich's Ataxia - Pipeline Insight, 2021 - Product Thumbnail Image

Friedreich's Ataxia - Pipeline Insight, 2021

  • Clinical Trials
  • May 2021
  • Global
From
From
From
From
From
From
Friedreich Ataxia - Global Clinical Trials Review, 2022 - Product Thumbnail Image

Friedreich Ataxia - Global Clinical Trials Review, 2022

  • Clinical Trials
  • February 2022
  • 91 Pages
  • Global
From
Friedreich Ataxia - Global Clinical Trials Review, H2, 2021 - Product Thumbnail Image

Friedreich Ataxia - Global Clinical Trials Review, H2, 2021

  • Clinical Trials
  • December 2021
  • 90 Pages
  • Global
From
Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2020 - Product Thumbnail Image

Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 114 Pages
  • Global
From
Loading Indicator

Ataxia is a neurological disorder that affects the coordination of movement. Ataxia drugs are used to treat the symptoms of this disorder, which can include difficulty walking, speaking, and swallowing. These drugs are part of the larger Central Nervous System (CNS) drug market, which includes drugs used to treat a variety of neurological and psychiatric disorders. Ataxia drugs are typically prescribed to improve coordination and balance, as well as to reduce the risk of falls. Ataxia drugs are typically divided into two categories: symptomatic and disease-modifying. Symptomatic drugs are used to reduce the symptoms of ataxia, while disease-modifying drugs are used to slow the progression of the disorder. Common symptomatic drugs include benzodiazepines, anticholinergics, and anticonvulsants. Disease-modifying drugs include immunomodulators, gene therapy, and stem cell therapy. Some companies in the Ataxia Drug market include AbbVie, Biogen, Merck, Novartis, and Pfizer. Show Less Read more